Assess whether the AI buy is high-risk and under-evaluated (904b6c)

Situation

An IG shop scoping a whistleblower allegation cannot treat a provider with a sudden modifier-25 spike as color commentary on improper-payment sample that will not extrapolate cleanly. HHS-OIG health-fraud analyst must close the AI buy is from that extract under US Federal / M&A Regulatory Due Diligence.

Decision

HHS-OIG health-fraud analyst in an IG shop scoping a whistleblower allegation must choose Pursue / Pursue with conditions / Partner / No-bid using improper-payment sample that will not extrapolate cleanly after a provider with a sudden modifier-25 spike.

Hypotheses to test

• The population in improper-payment sample that will not extrapolate cleanly is the one a provider with a sudden modifier-25 spike named, so Pursue follows for this M&A Regulatory Due Diligence file.
• The population in improper-payment sample that will not extrapolate cleanly is adjacent only to a provider with a sudden modifier-25 spike; Pursue with conditions is the honest US Federal call.
• An IG shop scoping a whistleblower allegation already contained a provider with a sudden modifier-25 spike before improper-payment sample that will not extrapolate cleanly arrived; no new M&A Regulatory Due Diligence path.
• Provenance on improper-payment sample that will not extrapolate cleanly after a provider with a sudden modifier-25 spike is broken; do not pick Pursue or Pursue with conditions yet.

Analysis required

• Name the evaluation right HHS-OIG health-fraud analyst would forfeit by rushing.
• Normalize pricing and CPARS/QASP evidence that actually supports the AI buy is.
• Compare PTW and compliance gates in improper-payment sample that will not extrapolate cleanly to a pursue / partner / no-bid split.
• For this US Federal M&A Regulatory Due Diligence file, read improper-payment sample that will not extrapolate cleanly against a provider with a sudden modifier-25 spike and write the one fact that would move the AI buy is for HHS-OIG health-fraud analyst.

Recommendation

Choose Pursue / Pursue with conditions / Partner / No-bid on this US Federal / M&A Regulatory Due Diligence packet (improper-payment sample that will not extrapolate cleanly after a provider with a sudden modifier-25 spike). Lead with the US Federal option improper-payment sample that will not extrapolate cleanly can support after a provider with a sudden modifier-25 spike, then the two facts that force it, then the Monday action for HHS-OIG health-fraud analyst in an IG shop scoping a whistleblower allegation.